249 related articles for article (PubMed ID: 35444283)
1. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
Gallo D; Young JTF; Fourtounis J; Martino G; Álvarez-Quilón A; Bernier C; Duffy NM; Papp R; Roulston A; Stocco R; Szychowski J; Veloso A; Alam H; Baruah PS; Fortin AB; Bowlan J; Chaudhary N; Desjardins J; Dietrich E; Fournier S; Fugère-Desjardins C; Goullet de Rugy T; Leclaire ME; Liu B; Bhaskaran V; Mamane Y; Melo H; Nicolas O; Singhania A; Szilard RK; Tkáč J; Yin SY; Morris SJ; Zinda M; Marshall CG; Durocher D
Nature; 2022 Apr; 604(7907):749-756. PubMed ID: 35444283
[TBL] [Abstract][Full Text] [Related]
2. PKMYT1: A Potential Target for CCNE1 Amplificated Colorectal Tumors.
Fang Y; Zhang X; Guo Y; Dong Y; Liu W; Hu X; Li X; Gao D
Cell Biochem Biophys; 2023 Sep; 81(3):569-576. PubMed ID: 37572218
[TBL] [Abstract][Full Text] [Related]
3. Targeting
Xu H; George E; Gallo D; Medvedev S; Wang X; Kryczka R; Hyer ML; Fourtounis J; Stocco R; Aguado-Fraile E; Petrone A; Yin SY; Shiwram A; Anderson M; Kim H; Liu F; Marshall CG; Simpkins F
Res Sq; 2024 Feb; ():. PubMed ID: 38410486
[TBL] [Abstract][Full Text] [Related]
4. CCNE1 Amplification and PKMYT1 Inhibition Are Synthetic Lethal.
Cancer Discov; 2022 Jul; 12(7):OF12. PubMed ID: 35522064
[TBL] [Abstract][Full Text] [Related]
5. Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.
Szychowski J; Papp R; Dietrich E; Liu B; Vallée F; Leclaire ME; Fourtounis J; Martino G; Perryman AL; Pau V; Yin SY; Mader P; Roulston A; Truchon JF; Marshall CG; Diallo M; Duffy NM; Stocco R; Godbout C; Bonneau-Fortin A; Kryczka R; Bhaskaran V; Mao D; Orlicky S; Beaulieu P; Turcotte P; Kurinov I; Sicheri F; Mamane Y; Gallant M; Black WC
J Med Chem; 2022 Aug; 65(15):10251-10284. PubMed ID: 35880755
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of the 19q12 amplicon in grade III breast cancers.
Natrajan R; Mackay A; Wilkerson PM; Lambros MB; Wetterskog D; Arnedos M; Shiu KK; Geyer FC; Langerød A; Kreike B; Reyal F; Horlings HM; van de Vijver MJ; Palacios J; Weigelt B; Reis-Filho JS
Breast Cancer Res; 2012 Mar; 14(2):R53. PubMed ID: 22433433
[TBL] [Abstract][Full Text] [Related]
8. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells.
Toledo CM; Ding Y; Hoellerbauer P; Davis RJ; Basom R; Girard EJ; Lee E; Corrin P; Hart T; Bolouri H; Davison J; Zhang Q; Hardcastle J; Aronow BJ; Plaisier CL; Baliga NS; Moffat J; Lin Q; Li XN; Nam DH; Lee J; Pollard SM; Zhu J; Delrow JJ; Clurman BE; Olson JM; Paddison PJ
Cell Rep; 2015 Dec; 13(11):2425-2439. PubMed ID: 26673326
[TBL] [Abstract][Full Text] [Related]
10. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract][Full Text] [Related]
11. Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Etemadmoghadam D; Weir BA; Au-Yeung G; Alsop K; Mitchell G; George J; ; Davis S; D'Andrea AD; Simpson K; Hahn WC; Bowtell DD
Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19489-94. PubMed ID: 24218601
[TBL] [Abstract][Full Text] [Related]
12. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
Au-Yeung G; Lang F; Azar WJ; Mitchell C; Jarman KE; Lackovic K; Aziz D; Cullinane C; Pearson RB; Mileshkin L; Rischin D; Karst AM; Drapkin R; Etemadmoghadam D; Bowtell DD
Clin Cancer Res; 2017 Apr; 23(7):1862-1874. PubMed ID: 27663592
[No Abstract] [Full Text] [Related]
13. High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
Aziz D; Lee C; Chin V; Fernandez KJ; Phan Z; ; ; Waring P; Caldon CE
J Pathol Clin Res; 2022 Jul; 8(4):355-370. PubMed ID: 35384378
[TBL] [Abstract][Full Text] [Related]
14. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD
Clin Cancer Res; 2013 Nov; 19(21):5960-71. PubMed ID: 24004674
[TBL] [Abstract][Full Text] [Related]
15. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.
Etemadmoghadam D; George J; Cowin PA; Cullinane C; Kansara M; ; Gorringe KL; Smyth GK; Bowtell DD
PLoS One; 2010 Nov; 5(11):e15498. PubMed ID: 21103391
[TBL] [Abstract][Full Text] [Related]
16. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.
Noske A; Brandt S; Valtcheva N; Wagner U; Zhong Q; Bellini E; Fink D; Obermann EC; Moch H; Wild PJ
Oncotarget; 2017 Feb; 8(9):14794-14805. PubMed ID: 27582547
[TBL] [Abstract][Full Text] [Related]
17.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
18. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
Cocco E; Lopez S; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; Menderes G; Zammataro L; Buza N; Hui P; Wong S; Zhao S; Bai Y; Rimm DL; Ratner E; Litkouhi B; Silasi DA; Azodi M; Schwartz PE; Santin AD
Br J Cancer; 2016 Jul; 115(3):303-11. PubMed ID: 27351214
[TBL] [Abstract][Full Text] [Related]
19. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
Kang EY; Weir A; Meagher NS; Farrington K; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Bolithon A; Popovic G; Leung B; Tang K; Lambie N; Millstein J; Alsop J; Anglesio MS; Ataseven B; Barlow E; Beckmann MW; Berger J; Bisinotto C; Bösmüller H; Boros J; Brand AH; Brooks-Wilson A; Brucker SY; Carney ME; Casablanca Y; Cazorla-Jiménez A; Cohen PA; Conrads TP; Cook LS; Coulson P; Courtney-Brooks M; Cramer DW; Crowe P; Cunningham JM; Cybulski C; Darcy KM; El-Bahrawy MA; Elishaev E; Erber R; Farrell R; Fereday S; Fischer A; García MJ; Gayther SA; Gentry-Maharaj A; Gilks CB; ; Grube M; Harnett PR; Harrington SP; Harter P; Hartmann A; Hecht JL; Heikaus S; Hein A; Heitz F; Hendley J; Hernandez BY; Polo SH; Heublein S; Hirasawa A; Høgdall E; Høgdall CK; Horlings HM; Huntsman DG; Huzarski T; Jewell A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Khabele D; Kommoss FKF; Kruitwagen RFPM; Lambrechts D; Le ND; Lener M; Lester J; Leung Y; Linder A; Loverix L; Lubiński J; Madan R; Maxwell GL; Modugno F; Neuhausen SL; Olawaiye A; Olbrecht S; Orsulic S; Palacios J; Pearce CL; Pike MC; Quinn CM; Mohan GR; Rodríguez-Antona C; Ruebner M; Ryan A; Salfinger SG; Sasamoto N; Schildkraut JM; Schoemaker MJ; Shah M; Sharma R; Shvetsov YB; Singh N; Sonke GS; Steele L; Stewart CJR; Sundfeldt K; Swerdlow AJ; Talhouk A; Tan A; Taylor SE; Terry KL; Tołoczko A; Traficante N; Van de Vijver KK; van der Aa MA; Van Gorp T; Van Nieuwenhuysen E; van-Wagensveld L; Vergote I; Vierkant RA; Wang C; Wilkens LR; Winham SJ; Wu AH; Benitez J; Berchuck A; Candido Dos Reis FJ; DeFazio A; Fasching PA; Goode EL; Goodman MT; Gronwald J; Karlan BY; Kommoss S; Menon U; Sinn HP; Staebler A; Brenton JD; Bowtell DD; Pharoah PDP; Ramus SJ; Köbel M
Cancer; 2023 Mar; 129(5):697-713. PubMed ID: 36572991
[TBL] [Abstract][Full Text] [Related]
20. CCNE1 amplification is associated with liver metastasis in gastric carcinoma.
Kim B; Shin HC; Heo YJ; Ha SY; Jang KT; Kim ST; Kang WK; Lee J; Kim KM
Pathol Res Pract; 2019 Aug; 215(8):152434. PubMed ID: 31178228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
